RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort - O'Sullivan, JM; Taylor, J; Gerds, A; Buckley, S; Harrison, CN; Oh, S; List, AF; Howard, K; Dreau, H; Hamblin, A; Mead, AJ (Springer Nature, 2023)